<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02564367</url>
  </required_header>
  <id_info>
    <org_study_id>GMBH-STO-0114</org_study_id>
    <secondary_id>2014-004116-11</secondary_id>
    <nct_id>NCT02564367</nct_id>
  </id_info>
  <brief_title>Feasibility Study of Adjuvant Treatment With S-1 in Patients After R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction</brief_title>
  <acronym>S-1 adjuvant</acronym>
  <official_title>Multicenter Phase I/II Feasibility Study of Adjuvant Treatment With S-1 in Patients After R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIO-Studien-gGmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nordic Pharma SAS</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taiho Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AIO-Studien-gGmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter trial in Germany:&#xD;
&#xD;
      Feasibility Study of Adjuvant Treatment with S-1 in Patients after R0-Resection of&#xD;
      Adenocarcinoma of the Stomach and Esophagogastric Junction with the aim to show the&#xD;
      feasibility and tolerability of adjuvant S-1 treatment in Caucasian patients and to determine&#xD;
      the recommended dose for the treatment regimen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be enrolled in one cohorts.&#xD;
&#xD;
      Cohort 1 consists of 30 patients who receive S-1 twice daily for 18 cycles (D1-14 q 3 wks).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 6, 2015</start_date>
  <completion_date type="Actual">March 6, 2020</completion_date>
  <primary_completion_date type="Actual">March 1, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of patients with discontinuation of S-1 due to intolerable adverse reactions</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>One-year relapse-free survival rate</measure>
    <time_frame>12 months</time_frame>
    <description>Mo local relapse or distant metastases within one year after start of adjuvant treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>relapse-free survival until end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>European Organisation for Research and Treatment of Cancer (EORTC) C30 questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One-year survival rate</measure>
    <time_frame>1 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>plasma concentration of Tegafur (FT)</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate the pharmacokinetics of FT</description>
  </other_outcome>
  <other_outcome>
    <measure>plasma concentration of 5-Fluorouracil (5-FU)</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate the pharmacokinetics of 5-FU</description>
  </other_outcome>
  <other_outcome>
    <measure>plasma concentration of Gimeracil (CDHP)</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate the pharmacokinetics of CDHP</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Adenocarcinoma,Stomach</condition>
  <condition>Adenocarcinoma, Esophagogastric Junction</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First Cohort 1:&#xD;
(n = 30 patients) 18 cycles S-1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1</intervention_name>
    <description>18 cycles S-1, orally administered twice daily D1-14, q 3 wks&#xD;
S-1 starting dose: 2 x 30 mg/m^2 body surface area (BSA), D1-14, q 3 wks First dose reduction: 2 x 25 mg/m^2 BSA, D1-14, q 3 wks Second dose reduction: 2 x 20 mg/m^2 BSA, D1-14, q 3 wks</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Teysuno</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient signed and dated informed consent before the start of any specific protocol&#xD;
             procedures&#xD;
&#xD;
          2. Adult Caucasian patients ≥ 18 years of age&#xD;
&#xD;
          3. Histologically confirmed diagnosis of adenocarcinoma of the stomach and&#xD;
             esophagogastric (EG) junction classified as uT2/uT3/uT4, any N category, M0 or any uT,&#xD;
             N+, M0 patient (for patients having received neoadjuvant chemotherapy) or pT2/pT3/pT4,&#xD;
             any N category, M0 or any pT, N+, M0 (for patients having received primary surgery)&#xD;
             according to Union international contre le cancer (UICC) TNM edition 7.&#xD;
&#xD;
          4. R0-resection after neoadjuvant treatment. However, patients can also be included if&#xD;
             neoadjuvant treatment could not be performed due to medical indication of primary&#xD;
             surgery (perforation, bleeding etc.) or was not performed due to understaging.&#xD;
&#xD;
          5. D2 lymph node dissection performed&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance status 0-1&#xD;
&#xD;
          7. Consent to translational research being performed on tumor tissue of the primary tumor&#xD;
             that had been removed during the resection surgery. Translational research will be&#xD;
             performed only upon completion of routine histological and pathological evaluations of&#xD;
             the tumor&#xD;
&#xD;
          8. Females of childbearing potential (FCBP) must have a negative pregnancy test within 7&#xD;
             days of the first application of study treatment and must agree to use effective&#xD;
             contraceptive birth control measures (Pearl Index &lt; 1) during the course of the trial&#xD;
             and for at least 6 months after last application of S-1.&#xD;
&#xD;
             Females of childbearing potential (FCBPs) should be included after a confirmed&#xD;
             menstrual period (only if applicable, i.e. still having menses) and must have a&#xD;
             negative highly sensitive pregnancy test within 7 days prior to the first application&#xD;
             of study treatment and must agree to use highly effective contraceptive birth control&#xD;
             measures (Pearl Index &lt; 1) during the course of the trial and for at least 6 months&#xD;
             after last application of S-1.&#xD;
&#xD;
             Such highly effective birth control methods include:&#xD;
&#xD;
               -  oral, intravaginal, or transdermal combined hormonal contraception associated&#xD;
                  with inhibition of ovulation&#xD;
&#xD;
               -  oral, injectable, or implantable progesterone-only hormonal contraception&#xD;
                  associated with inhibition of ovulation&#xD;
&#xD;
               -  intrauterine device&#xD;
&#xD;
               -  intrauterine hormone-releasing system&#xD;
&#xD;
               -  bilateral tubal occlusion&#xD;
&#xD;
               -  commitment to complete abstinence from heterosexual contact&#xD;
&#xD;
             A female subject following menarche is considered to be of childbearing potential&#xD;
             unless she is naturally amenorrhoeic for ≥ 1 year without an alternative medical&#xD;
             reason, or unless she is permanently sterile (permanent sterilisation methods include&#xD;
             hysterectomy, bilateral salpingectomy and bilateral oophorectomy).&#xD;
&#xD;
          9. Males must agree not to father a child during the course of the trial and for at least&#xD;
             6 months after last administration of S-1 and must agree to use condoms during the&#xD;
             course of the trial and for at least 6 months after last administration of S-1 in case&#xD;
             of sexual intercourse with FCBP or pregnant female.&#xD;
&#xD;
         10. Patient must be able to take medication orally within eight weeks after surgery at the&#xD;
             start of S-1.&#xD;
&#xD;
         11. Normal cardiac function demonstrated by Electrocardiogram (ECG) and echocardiogram&#xD;
             (LVEF ≥ 55%)&#xD;
&#xD;
         12. Adequate bone marrow, hepatic and renal function defined as&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1.0 x 10^9/L&#xD;
&#xD;
               -  Haemoglobin ≥ 9 g/dL&#xD;
&#xD;
               -  Platelets ≥ 100 x 10^9/L&#xD;
&#xD;
               -  Albumin ≥ 2.5 g/dL&#xD;
&#xD;
               -  Total bilirubin ≤ 2 mg/dL&#xD;
&#xD;
               -  GOT/AST and GPT/ALT ≤ 3 x Upper normal limit (ULN)&#xD;
&#xD;
               -  Calculated creatinine clearance according to MDRD equation ≥ 50 mL/min&#xD;
&#xD;
         13. Patient's legal capacity to consent to study participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Metastatic disease (exclusion of metastatic disease by a postoperative CT or MRI scan&#xD;
             of thorax and abdomen within 3 weeks prior to start of adjuvant therapy)&#xD;
&#xD;
          2. Polyneuropathy &gt; grade 1 (NCI CTCAE version 4.0)&#xD;
&#xD;
          3. Evidence of ascites or liver cirrhosis&#xD;
&#xD;
          4. Patient is pregnant or breast-feeding&#xD;
&#xD;
          5. Patient underwent a major surgical procedure, open biopsy, or significant traumatic&#xD;
             injury within 28 days prior to study enrollment, or there is an anticipated need for&#xD;
             major surgical procedure during the course of the study.&#xD;
&#xD;
          6. Heart failure ≥ NYHA functional classification system grade 2&#xD;
&#xD;
          7. Myocardial infarction, unstable angina, cardiac angioplasty or stenting procedure&#xD;
             within the last 6 months.&#xD;
&#xD;
          8. Medical history of pulmonary fibrosis or interstitial lung disease (ILD)&#xD;
&#xD;
          9. Active or uncontrolled bacterial, viral, or fungal infection that requires systemic&#xD;
             treatment&#xD;
&#xD;
         10. Known HIV-, HBV-, and HCV-infection&#xD;
&#xD;
         11. Concurrent disease or condition that would make the patient inappropriate for study&#xD;
             participation or would interfere with the patient's safety.&#xD;
&#xD;
         12. Psychological, familial, sociological, or geographical conditions that do not permit&#xD;
             compliance with the protocol.&#xD;
&#xD;
         13. Any cancer therapy (chemotherapy, radiation therapy, biologic therapy, immunotherapy,&#xD;
             or hormonal therapy) after resection surgery or requirement for concurrent cancer&#xD;
             treatment during study treatment with S-1.&#xD;
&#xD;
         14. Participation in another clinical trial or treatment with an investigational drug&#xD;
             after surgery and during study treatment with S-1.&#xD;
&#xD;
         15. Known immediate or delayed hypersensitivity to any of the active substances of S-1&#xD;
             (tegafur, gimeracil, and oteracil) or to any of the excipients or to drugs chemically&#xD;
             related to S-1 (e.g. 5-fluorouracil)&#xD;
&#xD;
         16. History of severe and unexpected reactions to fluoropyrimidine therapy&#xD;
&#xD;
         17. Known dihydropyrimidine dehydrogenase (DPD) deficiency&#xD;
&#xD;
         18. Treatment with DPD inhibitors, including sorivudine or its chemically related&#xD;
             analogues such as brivudine within 4 weeks before start of study drug or during study&#xD;
             treatment&#xD;
&#xD;
         19. Previous or concurrent malignant tumor disease other than underlying tumor disease&#xD;
             with the exception of cervical cancer in situ, adequately treated basal cell carcinoma&#xD;
             or squamous cell carcinoma of the skin, superficial bladder tumors (Ta, Tis, and T1)&#xD;
             or any curatively treated tumors &gt; 5 years prior to enrolment&#xD;
&#xD;
         20. Known alcohol abuse or drug addiction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Volker Heinemann, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum der Universität München, Campus Großhadern</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum der Universität München, Campus Großhadern</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 10, 2015</study_first_submitted>
  <study_first_submitted_qc>September 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2015</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

